Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Phase 2 trial (NCT06196203) is recruiting with primary completion in 2026. No results posted or reported; only prior Ph1b data cited. Evidence insufficient for positive or negative classification on this exact trial.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
NO_DECISIONDismissed94% confidencemanual-chat-review
Will the results be positive?
The AK117 HR-MDS trial was still recruiting on ClinicalTrials.gov, and Akeso later said only that enrollment had completed, not that efficacy results were positive or negative.
Found Apr 4, 2026, 8:52 PMReviewed Apr 4, 2026, 10:33 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 efficacy readout is publicly available. The record still shows NCT06196203 as ongoing/recruiting, and later sponsor coverage says enrollment completed but gives no HR-MDS Phase 2 results or interpretation. Without an exact-trial readout, the outcome cannot be classified positive or negative.
Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:30 PM
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 efficacy readout was found. The record was still active/recruiting in early 2025, Akeso announced first US patient enrollment in August 2024, and Akeso’s 2025 H1 materials say 1L MDS Phase 2 enrollment completed—not results disclosed. That is insufficient to call the outcome positive or negative.
Found Apr 2, 2026, 5:14 PMReviewed Apr 3, 2026, 4:48 PM
ClinicalTrialsclinicaltrials.govJan 9, 2024, 12:00 AM
Study Details | NCT06196203 | A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
ClinicalTrials.gov lists NCT06196203 with first posting on Jan 9, 2024 and last update posted Feb 11, 2025; no posted efficacy readout was identified from this record.
Sponsorakesobio.comAug 6, 2024, 12:00 AM
First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome
Akeso said on Aug. 6, 2024 that the first US patient had been enrolled in this Phase 2 trial, indicating the study had only recently started rather than reported topline data.
Sponsorakesobio.comAug 1, 2025, 12:00 AM
Akeso 2025 Interim Results Presentation
Akeso’s 2025 H1 presentation lists 'Ligufalimab + Azacitidine' in 1L MDS as an 'MRCT phase II randomized double-blind' trial with 'Enrollment completed'—but gives no trial-specific efficacy outcome.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 efficacy readout was found. The exact study remains listed as ongoing/recruiting/enrollment completed without reported results, while the only favorable evidence located was earlier Phase 1b data, not this randomized Phase 2 trial. That makes the outcome not yet classifiable as positive or negative.
Found Mar 31, 2026, 9:41 PMReviewed Apr 1, 2026, 6:34 AM
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
I found no public Phase 2 efficacy readout for NCT06196203. The most recent trial-status sources indicate the study was still an ongoing trial with no results reported publicly as of March 2026, even though Akeso had said enrollment was completed in September 2025. Because there is no clear trial-specific positive or negative public readout yet, the correct classification is no_decision.
Found Mar 30, 2026, 4:31 AMReviewed Mar 30, 2026, 7:04 AM
Web Searchfdaaa.trialstracker.netMar 20, 2026, 12:00 AM
NCT06196203: An ongoing trial by Akeso
The page states: "This trial is ongoing. It must report results 10 months, 2 weeks from now." It also lists "Results Status Ongoing," "Completion date Jan. 31, 2026," "Actual reporting date None," and "Date last checked at ClinicalTrials.gov March 20, 2026."
Sponsorakesobio.comSep 16, 2025, 12:00 AM
Akeso CD47 antibody ligufalimab receives FDA Orphan Drug Designation
Akeso states in Chinese that, beyond AML, the randomized, double-blind, international multicenter Phase II clinical study of ligufalimab plus azacitidine for higher-risk MDS "has completed patient enrollment." The item does not provide efficacy or top-line outcome data for NCT06196203.
ClinicalTrialsclinicaltrials.gov
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
ClinicalTrials.gov identifies NCT06196203 as "A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes." The publicly available trial record is the study listing itself rather than a posted results announcement.